Open AccessRecently Approved and Under Investigation Drugs for Treating Patients with Heart Failure
Author(s) -
Yaniel Castro Torres,
Richard E. Katholi
Publication year - 2020
Publication title -
current cardiology reviews
Language(s) - English
Resource type - Journals
eISSN - 1875-6557
pISSN - 1573-403X
DOI - 10.2174/1573403x14666180702151626
Subject(s) - medicine , heart failure , ivabradine , spironolactone , valsartan , pharmacology , sacubitril, valsartan , ejection fraction , ranolazine , intensive care medicine , heart rate , blood pressure
Heart Failure (HF) represents a leading cause of morbidity and mortality worldwide. Despite the recent advances in the treatment of this condition, patients´ prognosis remains unfavorable in most cases. Sacubitril/valsartan and ivabradine have been recently approved to improve clinical outcomes in patients with HF with reduced ejection fraction. Drugs under investigation for treating patients with HF encompass many novel mechanisms including vasoactive peptides, blocking inflammatory- mediators, natriuretic peptides, selective non-steroidal mineralocorticoid-receptor antagonists, myocardial β3 adrenoreceptor agonists, inhibiting the cytochrome C/cardiolipin peroxidase complex, neuregulin-1/ErbB signaling and inhibiting late inward sodium current. The aim of this manuscript is to review the main drugs under investigation for the treatment of patients with HF and give perspectives for their implementation into clinical practice.